Violeta Serra
- Aging top 1%
- Oncology top 0.5%
- PARP inhibition in cancer therapy 18
- HER2/EGFR in Cancer Research 12
- Cancer-related Molecular Pathways 8
- Genetics top 1%
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 9
- Molecular Biology top 1%
- DNA Repair Mechanisms 18
- PI3K/AKT/mTOR signaling in cancer 12
-
- Cardiac Valve Diseases and Treatments 14
-
- Advanced Breast Cancer Therapies 11
- Co-authors
- Jordi RodónJosep TaberneroRodrigo DienstmannMaurizio ScaltritiMarta GuzmánPieter J.A. EichhornJosé BaselgaThomas von Zglinicki
- Journals
- Cancer Research (12 papers)Annals of Oncology (8 papers)Molecular Cancer Therapeutics (5 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Violeta Serra
86 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 127
- Aging 269
- Oncology 3.1k
- Genetics 742
- Cancer Research 1.0k
- Molecular Biology 4.2k
Countries citing papers authored by Violeta Serra
This map shows the geographic impact of Violeta Serra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Violeta Serra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Violeta Serra more than expected).
Fields of papers citing papers by Violeta Serra
This network shows the impact of papers produced by Violeta Serra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Violeta Serra. The network helps show where Violeta Serra may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Violeta Serra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 5 | |
| 3 | 2023 | 8 | |
| 4 | 2023 | 3 | |
| 5 | 2022 | 12 | |
| 6 | 2021 | 25 | |
| 7 | 2021 | 62 | |
| 8 | 2019 | 24 | |
| 9 | A decade of clinical development of PARP inhibitors in perspectivebreakdown → | 2019 | 495 |
| 10 | 2018 | 44 | |
| 11 | 2018 | 70 | |
| 12 | Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancerbreakdown → | 2016 | 511 |
| 13 | 2016 | 35 | |
| 14 | 2014 | 127 | |
| 15 | 2013 | 33 | |
| 16 | 2011 | 251 | |
| 17 | NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutationsbreakdown → | 2008 | 626 |
| 18 | 2008 | 378 | |
| 19 | 2005 | 95 | |
| 20 | 2005 | 56 |
About Violeta Serra
Violeta Serra is a scholar working on Aging, Oncology, Cancer Research, Cardiology and Cardiovascular Medicine and Molecular Biology, having authored 92 papers that have together received 7.5k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (18 papers), PARP inhibition in cancer therapy (18 papers), Cardiac Valve Diseases and Treatments (14 papers), PI3K/AKT/mTOR signaling in cancer (12 papers), HER2/EGFR in Cancer Research (12 papers), Advanced Breast Cancer Therapies (11 papers), Cancer Genomics and Diagnostics (9 papers) and Cancer-related Molecular Pathways (8 papers). The work is most often cited by research in Aging (269 citations), Oncology (3.1k citations), Genetics (742 citations), Cancer Research (1.0k citations) and Molecular Biology (4.2k citations). Violeta Serra has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Maurizio Scaltriti, Marta Guzmán, Pieter J.A. Eichhorn, José Baselga, José Baselga, Thomas von Zglinicki and Sarat Chandarlapaty. Their work appears in journals such as Cancer Research, Annals of Oncology, Molecular Cancer Therapeutics, JACC: Cardiovascular Interventions and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.